Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Urruticoechea, Ander
METALLICA, NCT04300790: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients	Completed	2	69	Europe	Alpelisib, BYL719, Metformin, Fulvestrant, Letrozole, Exemestane, Vildagliptin, Tamoxifen	MedSIR, Novartis	Breast Cancer	06/22	03/25
NCT05547321: Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.	Recruiting	1	120	Europe, US	OMTX705, NA at this moment, Pembrolizumab, Keytruda (trademark)	Oncomatryx Biopharma S.L.	Advanced Solid Tumor	10/24	10/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Urruticoechea, Ander
METALLICA, NCT04300790: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients	Completed	2	69	Europe	Alpelisib, BYL719, Metformin, Fulvestrant, Letrozole, Exemestane, Vildagliptin, Tamoxifen	MedSIR, Novartis	Breast Cancer	06/22	03/25
NCT05547321: Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.	Recruiting	1	120	Europe, US	OMTX705, NA at this moment, Pembrolizumab, Keytruda (trademark)	Oncomatryx Biopharma S.L.	Advanced Solid Tumor	10/24	10/24